SCHEMBL6476392

SCHEMBL6476392

[NH]C(=O)Nc1cccc2c1ccc1ccccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.56
GAA P10253 2/20 0.56
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
HPRT1 P00492 2/20 0.51
MAPT P10636 3/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
CHRNB2 P17787 1/20 0.48
CHRNB4 P30926 1/20 0.48
CHRNA3 P32297 1/20 0.48
CHRNA4 P43681 1/20 0.48
ALDH1A1 P00352 2/20 0.46
GSK3B P49841 1/20 0.46
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL569792 0.89 KDM4E (0.69) KDM4EGAANPC1RAB9ACYP1A2
SCHEMBL1567446 0.84 KDM4E (0.58) KDM4EGAANPC1RAB9ACYP1A2
SCHEMBL6476396 0.84 KDM4E (0.79) KDM4EGAANPC1RAB9ACYP1A2
SCHEMBL8982554 0.83 KDM4E (0.63) KDM4EGAANPC1RAB9ACYP1A2
SCHEMBL7003239 0.76 HPRT1 (0.58) KDM4EGAARAB9ACYP1A2CYP3A4
SCHEMBL6541282 0.75 HPRT1 (0.64) KDM4EGAARAB9ACYP1A2CYP3A4
SCHEMBL9572742 0.75 HPRT1 (0.64) KDM4EGAARAB9ACYP1A2CYP3A4
SCHEMBL21645599 0.74 HPRT1 (0.61) KDM4EGAARAB9ACYP3A4HPRT1
SCHEMBL6450246 0.74 KDM4E (0.62) KDM4EGAANPC1RAB9ACYP1A2
SCHEMBL11291466 0.74 NPC1 (0.79) KDM4EGAANPC1RAB9ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6930114-B2 Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors BAYER PHARMACEUTICALS CORPORATION (US) 2005-08-16 US disclosed
US-20040138249-A1 Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors BAYER PHARMACEUTICALS CORPORATION 2004-07-15 US disclosed
US-20030236276-A1 Pyrrolo[2.1-a]isoquinoline derivatives NIEWOHNER ULRICH (DE) 2003-12-25 US disclosed
EP-1347973-A1 PYRROLO (2.1-A) DIHYDROISOQUINOLINES AND THEIR USE AS PHOSPHODIESTERASE 10A INHIBITORS Bayer Aktiengesellschaft (DE) 2003-10-01 EP disclosed
WO-2003014116-A1 PYRROLO[2.1-A]ISOQUINOLINE DERIVATIVES BAYER CORPORATION (US) 2003-02-20 WO disclosed
WO-2003014117-A1 3-SUBSTITUTED PYRROLO[2.1-A]ISOQUINOLINE DERIVATIVES BAYER CORPORATION (US) 2003-02-20 WO disclosed
WO-2002048144-A1 PYRROLO (2.1-A) DIHYDROISOQUINOLINES AND THEIR USE AS PHOSPHODIESTERASE 10A INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2002-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236276-A1 Pyrrolo[2.1-a]isoquinoline derivatives PDE5A, PDE2A, PDE3A KDM4E 1821/4885GAA 904/4885NPC1 3905/4885
US-20040138249-A1 Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors PDE7B, PDE2A, PDE5A KDM4E 714/4885GAA 1560/4885NPC1 4294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.